For now, Novo Nordisk (NVO) CEO Mike Doustdar says it's business as usual for its weight-loss drug behemoth as healthcare giant CVS Health (CVS) undergoes a complicated breakup. "In some ways, I would say I don't see a material impact for us other than now we have to of course have two different negotiations and two different groups of people that we will speak to about our products and making sure that it finds it in their formulary, but being a popular product company makes it a lot easier than otherwise," Doustdar said on Sozzi Unleashed. Read more: Novo Nordisk CEO: Wegovy pill 'exceeded our expectations' CVS Health announced plans late Wednesday to break up its $117 billion healthcare empire into two standalone, publicly traded businesses.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.